Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Free Cash Flow history
Currency unavailable · from the cash flow
No Free Cash Flow data reported for this period type.
Free Cash Flow vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $351.8M USD | +1.4% | +49.8% | 4755.3% |
| LTM Sep 2026 | $249.32M USD | +54.0% | +28.3% | 275.5% | |
| LTM Jun 2026 | $132.17M USD | +256.3% | — | 46.9% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $123.86M USD | +46.4% | +100.8% | — |
| LTM Mar 2026 | $81.45M USD | -1.7% | +9.6% | — | |
| LTM Mar 2026 | $52.27M USD | +8.5% | -11.6% | 624.8% | |
| LTM Mar 2026 | $4.41M USD | +104.0% | — | 1.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +46.4% | +28.3% | 275.5% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.